+33 (0)4 34 35 95 08 / +33 (0)6 08 82 23 46
Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet – Saint-Étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability. This involves disrupting their anchorage to the bone, which has been found to be possible using a small chemical compound called C21. This innovative treatment can protect mice from bone loss associated with osteolytic diseases such as post-menopausal osteoporosis, rheumatoid arthritis and bone metastasis, without affecting bone formation. This research was published on 3 February 2015 in the journal Nature Communications.
© Inserm/Boivin, Georges
Three new members have been isolated and added to the Pandoravirus family by researchers at the Structural and Genomic Information Laboratory (CNRS/Aix‐Marseille Université), working with partners at the Large Scale Biology Laboratory (CEA/Inserm/Université Grenoble‐Alpes) and at CEA-Genoscope. This strange family of viruses, ...
What if immune system efficacy against cancerous cells could be reinforced by a diet in which calories are not reduced but nutrients are precisely determined? This what Inserm researchers from Université Côte d’Azur, through a study of the effects of restrictive diets ...
Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation. Virginie Vives, Gaëlle Cres, Christian Richard, Muriel Busson, Yann Ferrandez, Anne-Gaelle Planson, Mahel Zeghouf, Jacqueline Cherfils, Luc Malaval and Anne Blangy. Nature communications, 3 février 2015. DOI : 10.1038/ncomms7218.